Agave Health is Proving That Neurodiversity Care Is a Real Business
When we backed Ori Fruhauf and Eve Lise Mamane at Agave Health, we believed neurodiversity care was a massive, underserved opportunity hiding in plain sight. The proof points are stacking up.
Here’s what’s been happening:
- Now in-network across 7 states with four major payers, reaching 13+ million people
- Named to the 2026 Digital Health 100 by Digital Health New York
- Early claims-based analysis proves a 3.4:1 ROI for employers
- Verified, supervised, measured care with every therapist certified in the Unified Protocol
- One of the most prominent tech and AI companies in the world just launched Agave as an employee benefit
The Problem Is Bigger Than Most Employers Realize
Up to 15-20% of employees are neurodivergent. 1 in 3 adults with ADHD don’t receive care. Employer healthcare costs for employees with ADHD run up to 60% higher than those without. That’s $3,760 in excess cost per employee, driven by higher pharmacy, outpatient, inpatient, and ER utilization.
The impact doesn’t stop at wellbeing. It shows up in medical spend, absenteeism, and productivity loss across entire organizations.
Neurodiversity care isn’t a nice-to-have. It’s a measurable cost and performance lever.
Expanding Access, State by State
One of the biggest barriers in neurodiversity care isn’t clinical. It’s access. Months-long waitlists. Thousands of dollars out of pocket. A specialized team that most people can’t reach.
Agave has been systematically dismantling that. Now in-network across 7 states (NY, NJ, PA, FL, TX, CO, and CA) with major payers including Aetna, Blue Cross Blue Shield, UnitedHealthcare, and Cigna Healthcare, Agave has opened access to specialized ADHD diagnosis and therapy services for over 35 million members.
Most recently, they expanded into Texas, adding 13+ million people to that network.
Same-week access. Specialized care. Covered by insurance. This is what scaling equitable access actually looks like.
Recognized as One of Digital Health’s Best
Agave has been selected to the 2026 Digital Health 100, the annual list published by Digital Health New York.
This reflects real, earned progress. Over the past year, the team has proven that evidence-based neurodiversity care (starting with adult ADHD) can be both accessible and scalable inside our healthcare system. Growing adoption with employers and health plans. Expanding access across more states. Increasing confidence that neurodiversity is becoming a core pillar of modern behavioral health.
Setting a New Clinical Standard
Here’s the hard truth about “evidence-based” behavioral health: most solutions claim it, but can’t prove it. No training. No supervision. No outcomes measurement.
That’s not how Agave operates.
Agave has partnered with the Unified Protocol Institute to certify every therapist in the Unified Protocol, the gold-standard transdiagnostic CBT framework that treats the shared emotional roots across conditions, not just the label. Because ADHD almost never shows up alone. Anxiety, depression, substance use, chronic stress are the norm, not the exception.
Agave verifies their care. Supervises it. Measures it. That clinical rigor, championed by Dr. David Sitt and the Agave clinical team, is what separates a real solution from a checkbox.
The ROI Is Concrete
Agave’s early claims-based analysis shows a 3.4:1 ROI, driven by reductions in excess medical spend and indirect cost drivers like comorbid conditions, absenteeism, and productivity loss. Providing a neurodiversity-specific benefit can reduce cost burden by up to 76%, with savings of $1,234-$2,878 per employee.
That message is resonating. One of the most prominent tech and AI companies in the world has already launched Agave as a benefit for their employees, with early data showing a meaningful impact on productivity, and plans to expand access further.
87% of Agave members report improved ADHD symptoms and day-to-day functioning. Companies that prioritize disability inclusion report 30% higher profit margins, 28% higher revenue, and a 90% increase in employee retention. The business case isn’t complicated. It’s just been underbuilt. Until now.
The Turning Point and What’s on the Horizon
Neurodiversity care has been underfunded, underbuilt, and underestimated for too long. That’s changing. The clinical frameworks are maturing. The payer infrastructure is catching up. The employer demand is real and growing.
Agave is at the center of all of it. Building the right way, with rigor, with evidence, and with genuine urgency to reach the people who need care most.
We’re proud to be invested in this journey and even more excited about what comes next.
